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This article reviews information on the clinical significance 
of antibodies to antigens in the Raph, John Milton Hagen, I, 
Globoside, Gill, Rh-associated glycoprotein, FORS, JR, LAN, Vel, 
CD59, and Augustine blood group systems. Antibodies to many of 
the antigens in these groups are rarely encountered because of the 
high prevalence of the associated antigens in most populations. 
For many of these antibodies, the clinical significance—that is, 
the potential to cause reduced survival of transfused antigen-
positive red blood cells or a transfusion reaction (e.g., anti-P, 
anti-Jra, and anti-Lan), and/or hemolytic disease of the fetus and 
newborn (e.g., anti-RHAG4 and anti-Vel)—has been documented. 
For other antibodies, their prevalence is so rare that information 
on the clinical significance of their antibodies is not available 
(e.g., anti-FORS1). Immunohematology 2018;34:85–90.
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Raph Blood Group System
The Raph blood group system contains just one 
antigen, MER2 (RAPH1), located on the tetraspanin CD151 
glycoprotein (TM4SF).1,2 The true MER2– phenotype, 
associated with the presence of anti-MER2, is very rare and 
results from mutations in CD151, but there is a quantitative 
red blood cell (RBC) polymorphism in which RBCs of about 8 
percent of white individuals are serologically MER2–.2
Clinical Significance
There have been six reports of human alloantibodies to 
MER2. Three of the subjects were found to have a stop codon 
in the CD151 gene, which encodes a member of the tetraspanin 
family of proteins. These three individuals had nephropathy and 
deafness, and two of the three, who were siblings, also had skin 
lesions, deafness, and β-thalassemia minor. The fourth subject 
had missense mutation c.533G>A (p.Argl78His). Subjects 5 
and 6 shared missense mutation c.511C>T (p.Argl71Cys) as 
well as a synonymous single-nucleotide mutation (c.579A>G) 
and had no clinical features. Although the CD151 protein is 
critical to cell adhesion and signaling and is implicated in 
cancer progression, its significance in transfusion medicine is 
limited to only one report of a hemolytic transfusion reaction 
(HTR).3 Least-incompatible RBC units should be selected 
for transfusion to patients with anti-MER2.2 No information 
on anti-MER2 causing hemolytic disease of the fetus and 
newborn (HDFN) is available.4
John Milton Hagen Blood Group System
The John Milton Hagen (JMH) blood group system 
consists of six high-prevalence antigens that are recognized by 
the International Society of Blood Transfusion (ISBT) and are 
numbered sequentially from JMH1 through JMH6. Confirmed 
JMH variants are named with the first letter from the antibody 
maker’s first name following JMH (JMH2 named JMHK, 
JMH3 named JMHL, JMH4 named JMHG, JMH5 named 
JMHM, JMH6 named JMHQ).5 These antigens are located on 
the Sema7A protein.5,6 The chromosomal location of SEMA7A 
is 15q22.3-q23. JMH1 is the primary antigen in the system 
and is present in greater than 99 percent of all individuals. The 
JMH1– phenotype is more commonly acquired by depression 
of the antigen. This finding might explain the serologic 
observation of a positive direct antiglobulin test (DAT) seen in 
many individuals with anti-JMH.5
Clinical Significance
JMH1, commonly known as JMH, is most notable because 
transient depression of the antigen occurs, and (auto)anti-JMH 
may develop.5 JMH– patients with anti-JMH often have no 
history of transfusion or pregnancy. Of seven JMH antibodies, 
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five were IgG4 and two were IgG1, although IgG3 anti-JMH 
has been described. There are numerous cases where patients 
with anti-JMH have been transfused with JMH+ blood 
with no adverse effects. One such patient received 20 units 
of JMH+ blood in 10 months, with the expected hemoglobin 
rise. There are no reports of JMH antibodies causing HDFN, 
which is unsurprising considering that JMH antigens are 
expressed very weakly on cord cells. One patient with anti-
JMH is reported to have experienced an acute intravascular 
HTR, but evidence that the JMH antibody was responsible is 
limited. Antibodies developed in the rare JMH variant types 
may cause reduced RBC survival.2 Today, rapid detection of 
JMH antibodies with recombinant SEMA7A protein and the 
particle gel immunoassay has been developed.7
I Blood Group System
The I antigen, together with i, used to be part of the 
Ii blood group collection. The gene encoding the I β-1, 
6-N-acetylglucosamine transferase (IGNT/GCNT2) respon-
sible for converting i active straight chains of carbohydrates to 
I active branched chains has been cloned,8 and some mutations 
responsible for adult i phenotype have been identified.9,10 
Hence, I has been promoted to the I blood group system 
comprising only a single antigen, the I antigen, and i remains 
in the Ii collection. RBCs from adults predominantly express 
I antigens and only low levels of i antigens, higher levels of 
the latter predominate in fetal and neonatal RBCs. In a small 
number of individuals, only very low levels of I can be detected, 
and their RBCs show high levels of i (adult i phenotype). This 
phenotype is believed to result from lack of activity of the I 
branching transferase, a product of the GCNT2 gene.2
Clinical Significance
Potent cold reactive antibodies responsible for cold 
agglutinin disease are usually of I specificity. These antibodies 
are generally monoclonal and are usually IgM, but IgG 
autoanti-I can also occur. They directly agglutinate I+ RBCs at 
4°C with varying thermal amplitude but are generally inactive 
above 30°C. One autoanti-I active at 30°C caused an acute 
HTR in a small child when 2 units of blood were transfused 
immediately after removal from the refrigerator. Transient, 
polyclonal, or oligoclonal autoanti-I may arise from infection, 
most typically by Mycoplasma pneumoniae.
Alloanti-I of high titer is rare and usually presents in the 
sera of i adults. These antibodies are almost invariably IgM 
and are active only at low temperatures. Rare examples may 
be hemolytic and have a thermal range up to 37°C, and some 
anti-I with a thermal range below 37°C can cause shortened 
survival of transfused I+ RBCs. One anti-I became potentially 
clinically significant after transfusion of 6 units of I+ blood. 
Globoside Blood Group System
The P blood group antigen of the Globoside system is a 
glycolipid structure, also known as globoside, on the RBCs 
of almost all individuals worldwide. The P antigen (Gb4) is 
intimately related to the Pk and NOR (P1PK4) antigens.
The molecular genetic basis of globoside deficiency is the 
absence of functional P synthase caused by mutations at the 
B3GALNT1 locus. Other related glycolipid structures, the 
LKE and PX2 antigens, remain in the Globoside blood group 
collection pending further evidence concerning the genes and 
gene products responsible for their synthesis.11
Clinical Significance
Anti-P is found in the serum of all Pk individuals and 
can be separated from serum of p individuals by adsorption 
with P1k or P2k cells or by inhibition with hydatid cyst fluid.2 
When complement is present, anti-P will hemolyze P1 or P2 
phenotype RBCs.2 P antibodies are IgM and often also IgG, are 
usually reactive at 37°C, and can cause severe intravascular 
HTRs. Autoanti-P is associated with paroxysmal cold 
hemoglobinuria. P antigen is also a receptor of parvovirus B19.
Cytotoxic IgM and IgG3 antibodies directed against P or 
Pk antigens are associated with a higher-than-normal rate of 
spontaneous abortion in women with the rare p, P1k, and P2k 
phenotypes.4
Gill Blood Group System
The Gill blood group system was added to the list of 
systems already recognized by the ISBT in 2002. GIL, the only 
antigen of the Gill system, is an antigen of high prevalence 
located on the water and glycerol channel aquaporin-3 
(AQP3).2,12 The GIL– phenotype results from homozygosity 
for a splice mutation in AQP3. Anti-GIL has been identified in 
five Gil– white women who had been pregnant at least twice.2
Clinical Significance
Five examples of anti-GIL have been identified, all in 
white women who had been pregnant at least twice. No GIL– 
individual was found by screening 23,251 white American and 
2841 African American women with anti-GIL. RBCs from two 
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of the babies of mothers with anti-GIL gave a positive DAT, 
but there were no clinical symptoms of HDFN. Anti-GIL may 
have been responsible for an HTR, and results of monocyte 
monolayer assay (MMA) with two GIL antibodies suggested a 
potential to cause accelerated destruction of transfused GIL+ 
RBCs.2
The Rh-Associated Glycoprotein Blood Group 
System
In 2010, the recognition that three RBC surface 
antigens were located on RhAG encoded by RHAG led to 
the establishment of a new blood group system. Two high-
prevalence antigens, Duclos (RHAG1) and DSLK (RHAG3), 
two low-prevalence antigens, OI(a) and (RHAG2), and RHAG4, 
have serologic characteristics suggestive of expression on 
RhAG, but RHAG4 has been shown to not exist and is under 
investigation by ISBT to be retracted.13
Clinical Significance
No data are available.4
FORS Blood Group System
This blood group system has been named FORS after its 
original finder, Lund professor John Forssman. The FORS 
antigen (originally recognized as the Apae phenotype) was 
discovered by weak reactivity of RBCs against polyclonal 
anti-A reagents, reactivity against the lectin Helix pomatia 
(snail anti-A), and no reactivity with the plant anti-A1 lectin, 
Dolichos biflorus, in two different families. Genomic analysis 
of the ABO locus in both samples revealed that they were 
genetically group O, and the reactivity described must be due 
to other phenomena.14,15
Clinical Significance
The clinical significance of anti-FORS1 is not known.4
JR Blood Group System
The JR blood group system (ISBT 032) consists of one 
antigen, Jra, which is highly prevalent in all populations (>99%). 
Jra is located on the ABCG2 transporter, a multipass membrane 
glycoprotein (also known as the breast cancer resistance protein 
[BCRP]), which is encoded by the ABCG2 gene on chromosome 
4q22.1.16–19 The rare Jr(a–) phenotype has been found mostly 
in Japanese and other Asian populations, but also in people 
of northern European ancestry, in Bedouin Arabs, and in one 
Mexican individual. The rare Jr(a–) phenotype mostly results 
from recessive inheritance of ABCG2 null alleles caused by 
frameshift or nonsense changes.17,20–22 To date, more than 25 
different mutations responsible for the absence of ABCG2 as 
well as mutations giving rise to weakened Jra expression have 
been identified.16
Clinical Significance
ABCG2 expression levels in cord RBCs are higher than 
those in adult RBCs, and the change of ABCG2 expression 
in erythroid lineage cells may influence the clinical course 
of fetal anemia with anti-Jra.23 Anti-Jra may be stimulated 
by transfusion or pregnancy and has been detected in 
untransfused Jr(a–) women during their first pregnancy.24 
Most anti-Jra are IgG1 and sometimes IgG3. Anti-Jra may 
fix complement, can be a dangerous antibody in pregnancy, 
and has been implicated in severe and fatal HDFN; in other 
pregnancies with anti-Jra, however, indications of HDFN 
have been no more than a positive DAT on cord cells or 
mild neonatal jaundice. Many transfusions of Jr(a+) RBCs 
to patients have resulted in no signs of hemolysis, although 
incompatible transfusion may cause a sharp rise in the titer 
of anti-Jra, resulting in signs of an acute HTR in subsequent 
transfusions. A patient with anti-Jra developed rigors after 
transfusion of 150 mL crossmatch-incompatible blood. Least-
incompatible RBC units may be suitable for transfusion to 
most patients with anti-Jra, but Jr(a–) RBCs should be selected 
in cases where the anti-Jra is of high titer.2
LAN Blood Group System
LAN (Langereis) was officially recognized by the ISBT in 
2012 as the 33rd human blood group system. It consists of one 
high-prevalence antigen, Lan (LAN1).25 The ABCB6 protein is 
the carrier of the Lan blood group antigen.16,25 The ABCB6 gene 
(chromosome 2q36, 19 exons) encodes the ABCB6 polypeptide, 
known as a porphyrin transporter. The exceptional Lan– 
individuals do not express ABCB6 (Lannull phenotype) owing 
to several different frameshift and missense mutations.25 To 
date, more than 40 ABCB6 alleles that encode Lan– or Lan+w 
phenotypes have been described,26 and quantitation of Lan 
antigen in Lan+, Lan+w, and Lan– phenotypes have been 
performed.27 Despite the Lan antigen role in erythropoiesis 
and detoxification of cells, Lan– individuals do not appear to 
demonstrate susceptibility to any disease.
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Clinical Significance
Anti-Lan has been reported in two African American 
individuals as well as in other populations including 
Caucasians and Asians and may be stimulated by transfusion 
or pregnancy. The original anti-Lan was responsible for an 
immediate HTR characterized by fever and chills. There is 
no report of naturally occurring alloanti-Lan; none of the 
Lan– siblings of the Lan– propositi have anti-Lan. Anti-Lan 
has been described as having variable clinical significance, 
either for HTRs (none to severe) or HDFN (none to mild).25 
Lan alloantibodies are mostly IgG1 and IgG3, although IgG2 
and IgG4 may also be present. Some anti-Lan fix complement; 
others do not.2 Despite challenging conditions caused by the 
scarcity of Lan– donors worldwide, ideally Lan– RBCs should 
be selected for transfusion to patients with anti-Lan, especially 
individuals with a high-titer antibody,2,25 although least 
incompatible RBCs may be suitable for patients with weak 
examples of the antibody. The only autoanti-Lan was reported 
in a patient with mild autoimmune hemolytic anemia (AIHA) 
with depressed Lan antigen expression.2
Vel Blood Group System
Vel is an RBC antigen that is expressed by more than 99.9 
percent of the population.28 The recognition of Vel dates to 
1952, when a patient, named Mrs. Vel, suffered a transfusion 
reaction due to the presence of an antibody that was found to 
agglutinate sera of over 10,000 individuals. The antibody was 
named anti-Vel.29
Recently, the SMIM1 protein was shown to carry the Vel 
blood group antigen. Using a high-density single nucleotide 
polymorphism array, Storry et al.30 identified the SMIM1 gene 
residing in a 97-kb region of homozygosity on chromosome 
1p36 in the vicinity of the RH locus. A frameshift deletion of 
17 nucleotides in exon 3 of SMIM1 is responsible for the Vel– 
phenotype.16,31,32 Genotype screening estimated that ~1 in 17 
Swedish blood donors is a heterozygous deletion carrier and 
~1 in 1200 is a homozygous deletion knockout.31
Clinical Significance
The high clinical significance of Vel is related to what 
happens to individuals with the Vel– phenotype upon 
transfusion or pregnancy. Vel alloantibodies are never 
naturally occurring, and most producers of anti-Vel have been 
transfused, yet Vel antibodies are predominantly IgM and 
fix complement. Of the two IgG anti-Vel, one was IgG1, and 
the other contained IgG1 and IgG3. Anti-Vel is a dangerous 
antibody, and patients with anti-Vel should be transfused 
with Vel– RBCs. The first anti-Vel and other examples since 
have caused severe immediate HTRs. Anti-Vel may be missed 
in compatibility testing if inappropriate methods are used.33 
Although many examples of anti-Vel have been found in 
pregnant women, anti-Vel does not usually cause HDFN, 
probably because most anti-Vel are predominantly IgM, and 
the Vel antigen is usually expressed weakly on neonatal RBCs.
Two examples of autoanti-Vel were responsible for (AIHA), 
although in one case, a nine-week-old infant, the RBCs gave a 
negative DAT.2
CD59
CD59, also known as the membrane inhibitor of reactive 
lysis (MIRL), homologous restriction factor (HRF), and 
membrane attack complex inhibitory factor (MACIF), is a cell 
surface glycoprotein of approximately 20 kDa that limits the 
activity of the terminal complement complex C5b-9 and is 
more effective than decay accelerating factor (DAF) or CD55 
in this respect.28,34 The first demonstration of anti-CD59 was 
in a patient homozygous for a CD59 deficiency, which led to 
the discovery of a new blood group system, CD59, and a null 
allele (c.146delA).
CD59 is attached by a glycosylphosphatidylinositol (GPI) 
anchor not only to erythrocytes but also to various other cellular 
membranes. Seven cases of an isolated CD59 deficiency due to 
three distinct null alleles of the CD59 gene have been published 
so far.34 As well as being cell-bound through its GPI anchor, 
soluble CD59 is also found in plasma, urine, and cerebrospinal 
fluid.
Absence of CD59 is associated with hemolytic anemia and 
with thrombosis as well as with other autoimmune diseases 
such as systemic lupus erythematosus.2
Clinical Significance
No data are available.
Augustine Blood Group System
Ata is a high-prevalence antigen found on the RBCs of over 
99 percent of individuals.35 The first literature referring to the 
Ata antibody, which can be responsible for severe HTRs and 
mild HDFN, dates to the 1960s. Applewhaite et al.36 identified 
an antibody with a novel specificity in the serum of Mrs. 
Augustine when the RBCs of her third child gave a positive 
DAT at birth. Her alloantibody, abbreviated as anti-Ata after 
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her name, reacted with more than 6600 blood donors tested 
at that time, indicating that Ata was a high-prevalence antigen. 
All anti-Ata producers reported thus far have been of African 
ancestry, like Mrs. Augustine.
Recently, it has been shown that SLC29A1 encoding the 
equilibrative nucleoside transporter 1 (ENT1) specifies a new 
candidate gene for a novel blood group system that includes the 
Ata antigen. Daniels et al.37 reported that a nonsynonymous 
SNP in SLC29A1 (rs45458701) is responsible for the At(a–) 
phenotype. Although all At(a–)-reported propositi are of 
African ancestry with functional ENT1, they identified three 
siblings of European ancestry who were homozygous for a 
null mutation in SLC29A1 (c.589+1G>C) and thus have the 
Augustinenull phenotype. These individuals lacking ENT1 
exhibit periarticular and ectopic mineralization, which 
confirms an important role for ENT1/SLC29A1 in human 
bone homeostasis,34 cardioprotection, and drug transport in 
erythrocytes.38
Clinical Significance
Ata antibodies are mostly IgG, but IgM could also be 
present and can directly agglutinate At(a+) RBCs. Of two IgG 
anti-Ata, one was IgG1, and the other consisted of IgG1, IgG3, 
and IgG4. Ata antibodies facilitate rapid destruction of 51Cr-
labeled At(a+) RBCs in vivo and give positive results in the in 
vitro functional assay, the MMA. Ideally, At(a–) RBCs should 
be selected for transfusion to patients with anti-Ata, although 
least incompatible RBC units may be suitable for patients with 
weak examples of the antibody.2
One anti-Ata caused an immediate HTR with chills and 
nausea during an RBC survival study, and another caused 
a severe delayed HTR after transfusion of multiple units of 
At(a+) RBCs. Despite numerous pregnancies involving anti-
Ata, only one of the infants had moderately severe HDFN 
requiring phototherapy.2 In three At(a–)-reported patients 
from the southern United States, the anti-Ata was concomitant 
with autoimmune disease.5
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